Can I read Roflumilast Foam Efficacy in Psoriasis on EtoBox?

Roflumilast Foam Efficacy in Psoriasis by m.zk.72724 is a document available to read on EtoBox.

What is Roflumilast Foam Efficacy in Psoriasis about?

The ARRECTOR Phase 3 clinical trial evaluated the safety and efficacy of roflumilast foam, 0.3%, in treating psoriasis of the scalp and body among 432 participants aged 12 and older. Results showed significant improvements in Scalp−Investigator Global Assessment (S-IGA) and Body−IGA (B-IGA) success rates at week 8 for the roflumilast group compared to the vehicle group, with low rates of adverse events. The findings suggest that roflumilast foam may serve as an effective monotherapy option for patients with

Author

m.zk.72724

Language

EN